BioNTech SE

Healthcare · Biotechnology · Germany

Last price 87.715 USD (Oct 30, 2026, 2:19 PM EDT) · Market cap 22.03B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli...